Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Having a sense of the history of research and clinical practice is valuable. With that in mind, we now publish Journal Club articles that focus on historical papers that are of particular significance, a link from past to present.
The definition of gastrointestinal involvement in post-acute COVID-19 syndrome, its frequency and its pathophysiology are still not completely understood. Here, we discuss the emerging evidence supporting immunological signatures and the unique nature of the gastrointestinal tract in this syndrome.
The burgeoning field of intratumoural microbiome research has been driven by advances in next-generation sequencing technologies, with compelling evidence on the role of the microbiota in cancer initiation, progression and patient response to treatment. Here, we discuss new concepts of the tumour-associated microbiota and what is needed to advance the translational impact of these findings in gastrointestinal cancers.
Intestinal immune cell trafficking is a tightly regulated process involved in health and disease. This Review discusses the sphingosine 1-phosphate modulators as therapeutic agents in targeting leukocyte trafficking and inflammation in inflammatory bowel disease.
In this Review, Andersen and colleagues discuss exogenous and endogenous factors responsible for mutational signatures in hepatobiliary cancers such as hepatocellular carcinoma and biliary tract cancers. In addition, they explore the role of mutational signatures in hepatobiliary tumorigenesis.
Dysbiotic microbiome signatures are linked to type 2 diabetes mellitus and inflammatory bowel disease activity, relapse risk and treatment response. Here, Metwaly and colleagues review these signatures and discuss why integrative analyses of multi-omics data could generate fresh insight into the mechanisms underlying these diseases.
Multiomics advance our understanding of disease progression and can facilitate drug discovery. In this Perspective, current knowledge and applications of omics platforms in inflammatory bowel disease diagnosis and in identifying risk factors are discussed.
